Suppr超能文献

DOT1L 介导的 RAP80 甲基化促进 BRCA1 募集以引发 DNA 修复。

DOT1L-mediated RAP80 methylation promotes BRCA1 recruitment to elicit DNA repair.

机构信息

Shenzhen University International Cancer Center, Guangdong Key Laboratory of Genome Instability and Human Disease Prevention, Marshall Laboratory of Biomedical Engineering, Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518055, China.

Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen 518060, China.

出版信息

Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2320804121. doi: 10.1073/pnas.2320804121. Epub 2024 Aug 22.

Abstract

Breast Cancer Type 1 Susceptibility Protein (BRCA1) is a tumor-suppressor protein that regulates various cellular pathways, including those that are essential for preserving genome stability. One essential mechanism involves a BRCA1-A complex that is recruited to double-strand breaks (DSBs) by RAP80 before initiating DNA damage repair (DDR). How RAP80 itself is recruited to DNA damage sites, however, is unclear. Here, we demonstrate an intrinsic correlation between a methyltransferase DOT1L-mediated RAP80 methylation and BRCA1-A complex chromatin recruitment that occurs during cancer cell radiotherapy resistance. Mechanistically, DOT1L is quickly recruited onto chromatin and methylates RAP80 at multiple lysines in response to DNA damage. Methylated RAP80 is then indispensable for binding to ubiquitinated H2A and subsequently triggering BRCA1-A complex recruitment onto DSBs. Importantly, DOT1L-catalyzed RAP80 methylation and recruitment of BRCA1 have clinical relevance, as inhibition of DOT1L or RAP80 methylation seems to enhance the radiosensitivity of cancer cells both in vivo and in vitro. These data reveal a crucial role for DOT1L in DDR through initiating recruitment of RAP80 and BRCA1 onto chromatin and underscore a therapeutic strategy based on targeting DOT1L to overcome tumor radiotherapy resistance.

摘要

乳腺癌 1 型易感蛋白(BRCA1)是一种肿瘤抑制蛋白,可调节多种细胞途径,包括维持基因组稳定性所必需的途径。一种重要的机制涉及 BRCA1-A 复合物,该复合物在启动 DNA 损伤修复(DDR)之前由 RAP80 募集到双链断裂(DSB)。然而,RAP80 本身如何被募集到 DNA 损伤部位尚不清楚。在这里,我们证明了在癌细胞放射抵抗过程中,一种甲基转移酶 DOT1L 介导的 RAP80 甲基化与 BRCA1-A 复合物染色质募集之间存在内在相关性。在机制上,DOT1L 迅速被募集到染色质上,并在 DNA 损伤后在多个赖氨酸上甲基化 RAP80。然后,甲基化的 RAP80 对于与泛素化的 H2A 结合以及随后触发 BRCA1-A 复合物募集到 DSB 是必不可少的。重要的是,DOT1L 催化的 RAP80 甲基化和 BRCA1 的募集具有临床相关性,因为抑制 DOT1L 或 RAP80 甲基化似乎在体内和体外都能增强癌细胞的放射敏感性。这些数据揭示了 DOT1L 在 DDR 中的关键作用,通过启动 RAP80 和 BRCA1 到染色质上的募集,并强调了基于靶向 DOT1L 以克服肿瘤放射治疗抵抗的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1110/11363320/739610795ff2/pnas.2320804121fig01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验